Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial
Published Online: 2019-12-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: DW Lee•DY Oh•EK Cho•GM Kim•Gun Min Kim•HJ Kim•HJ Kim•HK Ahn•Han Jo Kim•Hee Kyung Ahn•Hee-Jun Kim•IH Park•In Hae Park•JE Kim•JE Lee•JH Ahn•JH Cho•JH Jung•JH Kim•JH Lim•JH Sohn•JH Yu•JI Lee•JK Cheon•JS Ahn•JY Hur•JY Kim•Jee Hyun Kim•Ji-Yeon Kim•Jin-Seok Ahn•Jong In Lee•Joohyuk Sohn•KE Lee•KH Jung•KH Lee•KJ Suh•KS Lee•Kyoung Eun Lee•Kyung Hae Jung•Kyung-Hun Lee•MH Chang•MH Kim•MH Lee•MS Ahn•MS Kim•Moon Hee Lee•SA Im•SB Kim•SH Kim•SH Park•SJ Hong•SJ Koh•SJ Nam•SK Lee•SS Sim•ST Lim•SW Kim•SY Hyun•SY Kang•Seock-Ah Im•Seok Yun Kang•Su-Jin Koh•Sung-Bae Kim•TY Kim•TY Kim•Tae-Yong Kim•WY Park•YH Im•YH Park•YJ Kim•YL Choi•YW Choi•Yeon Hee Park•Young-Hyuck Im
